The Drug Evaluation Center of the State Food and Drug Administration released the "Annual Report on the Current Status of Clinical Trials for New Drug Registration in China (2020)"

In order to fully grasp the progress of clinical trials of new drug registration in China and strengthen the capacity building of drug supervision, the Center for Drug Evaluation, based on the registration information of the drug clinical trial registration and information disclosure platform, conducted a comprehensive analysis of the current status of clinical trials for new drug registration in China for the first time, and wrote and formed the "Chinese New Drugs" Annual Report on the Status of Registered Clinical Trials (2020)

Based on the drug clinical trial information registered in 2020, this report analyzes the clinical trials from the perspectives of sponsor type, drug type, trial variety, indications, trial stage, special population trial, clinical trial leader unit, start-up time and completion status, etc.

The follow-up drug review center will report on new drug registration clinical trials on an annual basis, relying on China's new drug registration clinical trial registration data, focus on regulatory innovation, improve regulatory effectiveness, strengthen communication with the industry in promoting the modernization of drug regulatory capabilities, and increase information transparency.

Attachment: "Annual Report on the Current Status of Clinical Trials of New Drug Registration in China (2020)"

Drug Evaluation Center of the State Drug Administration

November 10, 2021

Related attachment serial number attachment name

1"Annual Report on the Current Status of Clinical Trials of New Drug Registration in China (2020)".